Lv1
96 积分 2025-09-17 加入
EASIX score predicts non‐relapse mortality and severe infection in elderly patients undergoing allo‐HSCT
25天前
已完结
Rare Lymphomas: Getting "a Bit Ahead"
1个月前
已关闭
Low-Dose Golidocitinib for Triple-Mutant (JAK1/STAT3/TET2) ITLPD-GI After DLBCL Remission
1个月前
已完结
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
1个月前
已完结
Golidocitinib and chidamide for refractory or relapsed peripheral T-cell lymphoma: A preliminary cost-effectiveness analysis in China
1个月前
已完结
Golidocitinib favorable for relapsed/refractory T-cell lymphoma
1个月前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
1个月前
已完结
Golidocitinib: First Approval
1个月前
已完结
Endothelial Activation and Stress Index Serves as a Predictor for Survival in Lymphoma‐Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Multicenter Cohort Study of Jiangsu Cooperative Lymphoma Group
1个月前
已完结
Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML ‐ M4 and AML ‐ M5 , Treated With Venetoclax Plus Azacitidine
2个月前
已关闭
皖公网安备34019202002308
